Periodontitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Periodontitis pipeline market research report provides comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects.

Key Targets in the Periodontitis Pipeline Market

The key targets in the periodontitis pipeline market are 16S Ribosomal RNA, C5a Anaphylatoxin Chemotactic Receptor 1, Complement C3, Exotoxin, Glutaminyl Peptide Cyclotransferase, and Lipopolysaccharide.

Key MoA in the Periodontitis Pipeline Market

The types of key MoA in the periodontitis pipeline market are 16S Ribosomal RNA Inhibitor, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Complement C3 Inhibitor, and Glutaminyl Peptide Cyclotransferase Inhibitor.

Key RoA in the Periodontitis Pipeline Market

The key routes of administration in the periodontitis pipeline market are intravenous, topical, parenteral, buccal, intraarticular, intracoronary, intramuscular, intraocular, intravenous drip, nasal, ophthalmic, subcutaneous, and sublingual. Intravenous has the highest pipeline products.

Periodontitis Pipeline Market, by RoA

Periodontitis Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Periodontitis Pipeline Market

The key molecule types in the periodontitis pipeline market are cell therapy, small molecule, synthetic peptide, fusion protein, peptide, protein, and subunit vaccine. Cell therapy has the highest number of pipeline products.

Periodontitis Pipeline Market, by Molecule Types

Periodontitis Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Periodontitis Pipeline Market

The key companies in the periodontitis pipeline market are PerioTrap Pharmaceuticals GmbH, Amyndas Pharmaceuticals LLC, Beijing SH biotechnology Co Ltd, Cellatoz Therapeutics Inc, Cells for Cells SA, Chengdu Shiliankangjian Biotechnology Co Ltd, Cytopeutics Pte Ltd, Denteric Pty Ltd, Geistlich Pharma AG, GEXVal Inc, and KIMS Pharmaceutical Co Ltd. PerioTrap Pharmaceuticals GmbH has the highest number of pipeline products.

Periodontitis Pipeline Market, by Companies

Periodontitis Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets 16S Ribosomal RNA, C5a Anaphylatoxin Chemotactic Receptor 1, Complement C3, Exotoxin, Glutaminyl Peptide Cyclotransferase, and Lipopolysaccharide
Key MoA 16S Ribosomal RNA Inhibitor, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Complement C3 Inhibitor, and Glutaminyl Peptide Cyclotransferase Inhibitor
Key RoA Intravenous, Topical, Parenteral, Buccal, Intraarticular, Intracoronary, Intramuscular, Intraocular, Intravenous Drip, Nasal, Ophthalmic, Subcutaneous, and Sublingual
Key molecule types Cell Therapy, Small Molecule, Synthetic Peptide, Fusion Protein, Peptide, Protein, and Subunit Vaccine
Key companies PerioTrap Pharmaceuticals GmbH, Amyndas Pharmaceuticals LLC, Beijing SH biotechnology Co Ltd, Cellatoz Therapeutics Inc, Cells for Cells SA,  Chengdu Shiliankangjian Biotechnology Co Ltd, Cytopeutics Pte Ltd, Denteric Pty Ltd, Geistlich Pharma AG, GEXVal Inc, and KIMS Pharmaceutical Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Periodontitis (Mouth And Dental Disorders).
  • The pipeline guide reviews pipeline therapeutics for Periodontitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Periodontitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Periodontitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Periodontitis (Mouth And Dental Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Periodontitis (Mouth And Dental Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Periodontitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Amyndas Pharmaceuticals LLC
Beijing SH biotechnology Co Ltd
Cellatoz Therapeutics Inc
Cells for Cells SA
Chengdu Shiliankangjian Biotechnology Co Ltd
Cytopeutics Pte Ltd
Denteric Pty Ltd
Geistlich Pharma AG
GEXVal Inc
KIMS Pharmaceutical Co Ltd
MetiMedi Pharmaceuticals Co Ltd
Noveome Biotherapeutics Inc
PerioTrap Pharmaceuticals GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Periodontitis – Overview

Periodontitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Periodontitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Periodontitis – Companies Involved in Therapeutics Development

Periodontitis – Drug Profiles

Periodontitis – Dormant Projects

Periodontitis – Discontinued Products

Periodontitis – Product Development Milestones

Featured News & Press Releases

Jun 04, 2020: Cellatose announces Korea-US patent registration

Aug 26, 2019: Amyndas Pharmaceuticals initiates phase 2a study of AMY-101 in adults with periodontal inflammation and gingivitis

Dec 13, 2017: Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-101

Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis

Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis

May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Periodontitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Periodontitis – Pipeline by Amyndas Pharmaceuticals LLC, 2022

Periodontitis – Pipeline by Beijing SH biotechnology Co Ltd, 2022

Periodontitis – Pipeline by Cellatoz Therapeutics Inc, 2022

Periodontitis – Pipeline by Cells for Cells SA, 2022

Periodontitis – Pipeline by Chengdu Shiliankangjian Biotechnology Co Ltd, 2022

Periodontitis – Pipeline by Cytopeutics Pte Ltd, 2022

Periodontitis – Pipeline by Denteric Pty Ltd, 2022

Periodontitis – Pipeline by Geistlich Pharma AG, 2022

Periodontitis – Pipeline by GEXVal Inc, 2022

Periodontitis – Pipeline by KIMS Pharmaceutical Co Ltd, 2022

Periodontitis – Pipeline by MetiMedi Pharmaceuticals Co Ltd, 2022

Periodontitis – Pipeline by Noveome Biotherapeutics Inc, 2022

Periodontitis – Pipeline by PerioTrap Pharmaceuticals GmbH, 2022

Periodontitis – Dormant Projects, 2022

Periodontitis – Dormant Projects, 2022 (Contd..1)

Periodontitis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Periodontitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Periodontitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Periodontitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Periodontitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Periodontitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.